Skip to main content
. 2018 Jul 4;12(5):1705–1718. doi: 10.1177/1557988318784152

Table 3.

Pairwise Comparison Within Group Over Time.

Outcome measure Group (I) Time (J) Time Mean differencea (I−J) SE p value 95% CI for differencea
Lower bound Upper bound
CGI-SF
Placebo Baseline Week 2 0.86* 0.22 .01 0.27 1.45
Baseline Week 4 1.21** 0.25 <.01 0.54 1.88
Baseline Week 6 1.62** 0.26 <.01 0.91 2.33
Bupropion Baseline Week 2 1.45*** 0.22 <.001 1.52 2.57
Baseline Week 4 1.96*** 0.25 <.001 1.58 2.74
Baseline Week 6 2.57*** 0.36 <.001 1.87 3.28
SDI-2-BM
 DSD Placebo Baseline Week 2 −3.51 1.49 .13 −7.56 0.54
Baseline Week 4 −3.25 1.69 .34 −7.85 1.35
Baseline Week 6 −2.81 1.82 .76 −7.76 2.14
Bupropion Baseline Week 2 −7.77*** 1.49 <.001 −11.81 −3.72
Baseline Week 4 −8.62*** 1.69 <.001 −13.22 −4.02
Baseline Week 6 −9.41*** 1.82 <.001 −14.35 −4.46
 SSD Placebo Baseline Week 2 −1.73 0.92 .38 −4.22 0.77
Baseline Week 4 −1.26 0.81 .73 −3.46 0.93
Baseline Week 6 −1.86 0.83 .17 −4.11 0.40
Bupropion Baseline Week 2 −1.48 0.92 .68 −3.97 1.02
Baseline Week 4 −1.51 0.81 .40 −3.70 0.69
Baseline Week 6 −1.19 0.83 .93 −3.44 1.06
 Total Placebo Baseline Week 2 −6.39 2.66 .12 −13.63 0.85
Baseline Week 4 −5.82 2.81 .25 −13.45 1.81
Baseline Week 6 −6.84 2.90 .13 −14.72 1.04
Bupropion Baseline Week 2 −11.30*** 2.66 <.001 −18.54 −4.06
Baseline Week 4 −11.56*** 2.81 <.001 −19.19 −3.94
Baseline Week 6 −11.77*** 2.90 <.001 −19.65 −3.89
Mal-IIEF-15 domain
 Erectile function Placebo Baseline Week 2 −0.87 1.45 1.00 −4.80 3.07
Baseline Week 4 −1.17 1.40 1.00 −4.96 2.63
Baseline Week 6 −1.24 1.38 1.00 −5.00 2.51
Bupropion Baseline Week 2 −1.50 1.45 1.00 −5.44 2.43
Baseline Week 4 −2.67 1.40 .36 −6.47 1.12
Baseline Week 6 −3.93* 1.38 .04* −7.68 −0.17
 Orgasmic function Placebo Baseline Week 2 −0.92 0.53 .53 −2.38 0.53
Baseline Week 4 −1.40 0.56 .09 −2.92 0.13
Baseline Week 6 −1.08 0.62 .51 −2.76 0.60
Bupropion Baseline Week 2 0.35 0.53 1.00 −1.10 1.80
Baseline Week 4 −0.46 0.56 1.00 −1.99 1.06
Baseline Week 6 −0.63 0.62 1.00 −2.31 1.05
 Sexual desire Placebo Baseline Week 2 −0.20 0.27 1.00 −0.93 0.53
Baseline Week 4 −0.49 0.29 .60 −1.29 0.31
Baseline Week 6 −0.88 0.31 .05 −1.72 −0.06
Bupropion Baseline Week 2 −0.86*** 0.27 <.001 −1.61 −0.16
Baseline Week 4 −1.31*** 0.29 <.001 −2.11 −0.52
Baseline Week 6 −1.68*** 0.31 <.001 −2.51 −0.85
 Intercourse Placebo Baseline Week 2 0.11 0.63 1.00 −1.61 1.83
 Satisfaction Baseline Week 4 −0.56 0.65 1.00 −2.34 1.22
Baseline Week 6 −0.33 0.66 1.00 −2.12 1.46
Bupropion Baseline Week 2 −0.37 0.63 1.00 −2.08 1.35
Baseline Week 4 −0.72 0.65 1.00 −2.49 1.06
Baseline Week 6 −1.63 0.66 .09 −3.42 0.16
 Overall satisfaction Placebo Baseline Week 2 −0.03 0.40 1.00 −1.10 1.04
Baseline Week 4 −0.09 0.37 1.00 −1.09 0.92
Baseline Week 6 −0.45 0.37 1.00 −1.46 0.56
Bupropion Baseline Week 2 −0.57 0.40 .91 −1.65 0.50
Baseline Week 4 −0.19 0.37 1.00 −1.20 0.81
Baseline Week 6 −0.54 0.37 .91 −1.55 0.47
 Total Placebo Baseline Week 2 −2.66 2.86 1.00 −10.43 5.11
Baseline Week 4 −3.89 2.65 .88 −11.10 3.31
Baseline Week 6 −4.19 2.71 .76 −11.57 3.18
Bupropion Baseline Week 2 −3.01 2.86 1.00 −10.78 4.76
Baseline Week 4 −5.32 2.65 .29 −12.52 1.88
Baseline Week 6 −8.37* 2.71 .02 −15.75 −1.00
Plasma TT (nmol/L) Placebo Baseline Week 6 −3.32 1.62 .05 −6.57 −0.07
Bupropion Baseline Week 6 −4.03* 1.56 .01 −7.15 −0.90
Plasma prolactin (μIU/ml) Placebo Baseline Week 6 3.94 18.61 .83 −33.45 41.33
Bupropion Baseline Week 6 13.70 17.88 .45 −22.23 49.63

Note. aAdjustment for multiple comparisons: Bonferroni with covariate daily methadone dosage and duration of the methadone usage. CGI-SF = Clinical Global Impression Scale adapted for Sexual Function; Mal-IIEF-15 = Malay version of the International Index of Erectile Function 15; SDI-2-BM = Malay version of the sexual desire inventory-2; DSD = dyadic sexual desire; SSD = solitary sexual desire; TT = total testosterone; SD, standard deviation; SE, standard error. nmol/L = nanomoles per liter; μIU/ml = macro international units per milliliter.

*

p < .05. **p < .01. ***p < .001.